Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05095519
PHASE2

Hepatocellular Carcinoma Imaging Using PSMA PET/CT

Sponsor: Peter MacCallum Cancer Centre, Australia

View on ClinicalTrials.gov

Summary

The purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging).

Official title: Hepatocellular Carcinoma Imaging Using PSMA PET/CT - a Prospective Pilot Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2021-09-08

Completion Date

2026-09-08

Last Updated

2025-07-16

Healthy Volunteers

No

Interventions

DRUG

18F-DCFPyL

18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection

Locations (4)

St Vincent's Hospital

Fitzroy, Victoria, Australia

Austin Health

Heidelberg, Victoria, Australia

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

The Royal Melbourne Hospital

Melbourne, Victoria, Australia